Ticker

DNLI

Denali Therapeutics Inc.

11 catalysts on file

DNLI

Denali Therapeutics Inc.

Approval Confirmed

AVLAYAH (tividenofusp alfa-eknm)

Hunter Syndrome (MPS II)

149d ago Mar 25, 2026

SEC 8-K verified 2mo ago

Countdown card →

DNLI

Denali Therapeutics Inc.

Approval Confirmed

AVLAYAH™

Hunter syndrome (MPS II)

149d ago Mar 25, 2026

SEC 8-K verified 2mo ago

Countdown card →

DNLI

Denali Therapeutics Inc.

PDUFA Confirmed

tividenofusp alfa

Hunter syndrome

138d ago Apr 5, 2026

SEC 8-K verified 2mo ago

Countdown card →

DNLI

Denali Therapeutics Inc.

Phase 2 Confirmed

BIIB122/DNL151

Parkinson’s disease

92d ago May 21, 2026

SEC 8-K verified 2mo ago

Countdown card →

DNLI

Denali Therapeutics Inc.

Phase 2 AI-extracted

SAR443122/DNL758

ulcerative colitis

52d ago ~ Jun 30, 2026

SEC 8-K verified 2mo ago

Countdown card →

DNLI

Denali Therapeutics Inc.

Phase 2 AI-extracted

BIIB122

Parkinson’s disease

52d ago ~ Jun 30, 2026

SEC 8-K verified 2mo ago

Countdown card →

DNLI

Denali Therapeutics Inc.

Phase 1 AI-extracted

TAK-594/DNL593

GRN-related frontotemporal dementia

T-minus 132 days ~ Dec 31, 2026

SEC 8-K verified 2mo ago

Countdown card →

DNLI

Denali Therapeutics Inc.

Phase 1 AI-extracted

DNL628

Alzheimer's disease

T-minus 313 days ~ Jun 30, 2027

SEC 8-K verified 2mo ago

Countdown card →

DNLI

Denali Therapeutics Inc.

Phase 2 AI-extracted

DNL126

Sanfilippo syndrome type A

Date TBD Date TBD

SEC 8-K verified 2mo ago

Countdown card →

DNLI

Denali Therapeutics Inc.

Phase 2 AI-extracted

AVLAYAH (tividenofusp alfa-eknm)

Hunter Syndrome (MPS II)

Date TBD Date TBD

SEC 8-K verified 2mo ago

Countdown card →

DNLI

Denali Therapeutics Inc.

Phase 2 AI-extracted

DNL593

GRN-related frontotemporal dementia (FTD-GRN)

Date TBD Date TBD

SEC 8-K verified 2mo ago

Countdown card →